Form D · Biotechnology
Turn Therapeutics Inc.
Westlake Village, CA · CIK 0002023016
Offering snapshot reported Aug 26, 2026 · SEC filing
- Reported sold
- $1.65M Indefinite offering
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $15K Reported outside-investor minimum
- First sale
- Aug 14, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 26, 2026 | Initial | $1,650,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595490
Source: Form D, filed Aug 26, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bradley Burnam | Director, Executive |
| Zuraiz Chaudhary | Executive |
| Martin William Dewhurst | Director |
| Andrew Gengos | Director |
| Neilesh Shailesh Ghodadra | Director, Executive |
| Arthur F Golden | Director |
| Kent Kester | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
250 North Westlake Blvd. #210
Westlake Village, CA, 91362
Phone: 8185644011
Westlake Village, CA, 91362
Phone: 8185644011